SCHEMBL4458277

SCHEMBL4458277

CS(=O)(=O)c1cc(N(c2ccc(Cl)nc2)C(c2cccnc2)c2cccnc2)cs1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.33
CYP2A6 P11509 1/20 0.33
CYP3A4 P08684 2/20 0.33
CYP3A5 P20815 2/20 0.33
SCN1A P35498 3/20 0.32
SCN5A Q14524 3/20 0.32
SCN8A Q9UQD0 3/20 0.32
ALDH1A1 P00352 2/20 0.32
NR1I2 O75469 1/20 0.32
SCN1B Q07699 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KCNA5 P22460 2/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
CYP19A1 P11511 1/20 0.31
HTR6 P50406 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466935 0.86 KCNA5 (0.36) CYP3A4CYP3A5ALDH1A1MEN1KMT2A
SCHEMBL4468111 0.82 PTGS2 (0.43) CYP2C19CYP2A6CYP3A4CYP3A5ALDH1A1
SCHEMBL4461909 0.82 TAAR1 (0.39) CYP2C19CYP2A6CYP3A4CYP3A5ALDH1A1
SCHEMBL4461686 0.78 CYP2A6 (0.46) CYP2C19CYP2A6ALDH1A1MEN1MAPT
SCHEMBL4462110 0.77 CYP2C19 (0.37) CYP2C19CYP2A6CYP3A4CYP3A5ALDH1A1
SCHEMBL4458988 0.73 CYP2A6 (0.39) CYP2C19CYP2A6ALDH1A1MEN1MAPT
SCHEMBL4460464 0.73 MEN1 (0.39) CYP2C19CYP2A6SCN1AALDH1A1MEN1
SCHEMBL4472068 0.71 TAAR1 (0.39) CYP3A4CYP3A5KCNA5PTGS1PTGS2
SCHEMBL4462079 0.71 CYP19A1 (0.51) CYP2A6CYP3A4CYP3A5ALDH1A1MAPT
SCHEMBL4456792 0.70 CYP3A4 (0.44) CYP3A4CYP3A5KCNA5PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 CYP2C19 2828/4885CYP2A6 2605/4885CYP3A4 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.